肺炎链球菌3型掩盖PCV13在加拿大成人住院CAP中的群体免疫效应
该研究基于加拿大五省成人医院主动监测,分析2010至2015年住院肺炎链球菌社区获得性肺炎(CAPSpn)和侵袭性肺炎链球菌病(IPD)的血清型分布与临床结局。肺炎链球菌阳性率从2011年15.9%降至2014年8.8%,2015年回升至12.9%;PCV13血清型CAPSpn占比从2010年8.3%降至2014年4.6%,2015年回升至6.3%,下降主要归因于7F和19A型,比例上升归因于3型。尽管存在群体免疫证据,PCV13血清型仍在住院CAPSpn成人中持续存在,占该人群所有CAP的5%至10%。
要点
- 肺炎链球菌阳性率2011年15.9%降至2014年8.8%,2015年回升至12.9%。
- PCV13血清型CAPSpn占比2010年8.3%降至2014年4.6%,2015年升至6.3%。
- PCV13血清型仍占住院CAPSpn成人所有CAP的5%至10%。
核心结论
- 主要由7F和19A型提供的群体免疫似乎被3型比例 concomitantly 增加部分掩盖。
- 尽管有群体免疫证据,PCV13血清型仍在加拿大成人住院CAPSpn中持续存在,占该人群所有CAP的5%至10%。
研究设计与样本
- 在加拿大五个省的成人医院对CAP和IPD进行主动监测,研究2010至2015年住院的≥16岁成人。
- IPD定义为从无菌部位分离出肺炎链球菌;菌血症和非菌血症CAPSpn分别通过血培养和痰培养或PCV13特异性尿抗原检测(UADPCV13)鉴定。
- 血清型通过Quellung反应、PCR或UADPCV13确定。
主要发现
- 在6687例进行了检测的CAP病例中,肺炎链球菌阳性率从2011年15.9%降至2014年8.8%,但2015年回升至12.9%。
- PCV13血清型CAPSpn占比从2010年8.3%降至2014年4.6%,但2015年回升至6.3%。
- 下降主要归因于7F和19A血清型,比例上升归因于3型。
- 菌血症和非菌血症CAPSpn呈现相似趋势。
- 30天死亡率、ICU入住和机械通气需求在CAPSpn和IPD病例中突出,但在研究年份间保持不变。
临床怎么用
- 在评估成人PCV13免疫获益时,需考虑3型比例上升可能部分掩盖7F和19A型带来的群体免疫效应。
- 住院CAPSpn成人中PCV13血清型仍持续存在,占所有CAP的5%至10%,提示成人PCV13免疫仍可能具有潜在价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was recently shown to be effective against PCV13-type invasive pneumococcal disease (IPD) and pneumococcal community acquired pneumonia (CAPSpn) in healthy adults aged ≥65 years, prompting many countries to re-assess adult immunization. In Canada, the potential benefits of adult PCV13 immunization were unclear given anticipated herd immunity from PCV13 childhood immunization introduced since 2010. This study describes the serotype distribution and clinical outcomes of Canadian adults aged ≥16 years, who were hospitalized with CAPSpn and IPD from 2010 to 2015. METHODS: Active surveillance for CAP and IPD was performed in adult hospitals across five Canadian provinces. IPD was identified when Streptococcus pneumoniae was isolated from sterile sites. Bacteremic and non-bacteremic CAPSpn were identified using blood culture, and sputum culture or PCV13-specific urine antigen detection (UADPCV13), respectively. Serotype was assigned using Quellung reaction, PCR, or UADPCV13. RESULTS: Of 6687 CAP cases where a test was performed, S. pneumoniae positivity decreased from 15.9% in 2011 to 8.8% in 2014, but increased to 12.9% in 2015. CAPSpn attributed to PCV13 serotypes followed a similar trend, dropping from 8.3% in 2010 to 4.6% in 2014, but increasing to 6.3% in 2015. The decline was primarily attributed to serotypes 7F and 19A, and the proportional increase to serotype 3. Similar trends were noted for bacteremic and non-bacteremic CAPSpn. Serious outcomes such as 30-day mortality, intensive care unit admission, and requirement for mechanical ventilation were prominent in CAPSpn and IPD cases, but remained unchanged over the study years. CONCLUSION: Herd immunity afforded primarily by serotypes 7F and 19A appears to be partly masked by a concomitant proportional increase of serotype 3. Despite evidence of herd immunity, these PCV13 serotypes remain persistent in Canadian adults hospitalized with CAPSpn, and represent between 5 and 10% of all CAP in this patient population.
引用
- LeBlanc JJ, ElSherif M, Ye L, et al. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). Vaccine. 2019. PMID: 31345638. doi:10.1016/j.vaccine.2019.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。